Results 141 to 150 of about 17,466 (191)

The role of deubiquitinating enzymes and their inhibitors in esophageal carcinoma (Review). [PDF]

Int J Oncol
Zhao Y, He C, Chen K, Sun N, He R, Li G.
europepmc   +1 more source

Tumor suppressor BAP1 emerges as a key regulator of metabolism and cell death in tumors. [PDF]

Front Cell Dev Biol
Fan K, Yao J, Wu S, Zhang Y.
europepmc   +1 more source

Glycolytic Reprogramming Mediated by the OTUD4-FXR1-HIF1A Axis Drives Gastric Cancer Progression. [PDF]

Int J Biol Sci
Wang F, Shao Y, Zhuang X, Liu X, Hu Y, Dai C, Chen J, Kuang Y, Wang G, Zhao Z, Cai N, Gu L, Zhou G, Chu H, Zhao H, Deng C, Zhang C.   +16 more
europepmc   +1 more source

MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer. [PDF]

Mol Cancer Res
Ma B, Zhang X, Kral AJ, Singh N, Deschênes A, Cifani P, Park Y, Tuveson DA, Krainer AR, Wan L.   +9 more
europepmc   +1 more source

Deubiquitinating enzymes-mediated post-translational modifications of ferroptosis regulates cancer drug resistance. [PDF]

Discov Oncol
Zhang L, Li M, Wang Y, Sun H, Lian H.
europepmc   +1 more source

Deubiquitinating enzymes in kidney diseases: Molecular mechanisms, pathological roles and therapeutic opportunities (Review). [PDF]

Mol Med Rep
Li Q, Ni Y, Li Z, Li J, Wang L.
europepmc   +1 more source

USP9X trims STAT1 to curb oncostatin M activity and intestinal inflammation. [PDF]

Cell Mol Immunol
Hegazy AN.
europepmc   +1 more source

A GJA1 Variant Triggers Earlier SPG4 Onset by Destabilizing Deubiquitinase VCPIP1 to Lower SPASTIN Levels. [PDF]

Mov Disord
Yang L, Chi H, Zhang Y, Wu D, Hu Y, Guo J, He Y, Fan J, Lv K, Cheng F, Xiao N, Peng Q, Dong Y, Wang L, Wu B, Zhong M, Liu T.   +16 more
europepmc   +1 more source

Targeting the OTU family: a core therapeutic strategy for reshaping the immunosuppressive microenvironment and reversing drug resistance in HCC by coordinating the autophagy-ferroptosis balance. [PDF]

Cell Death Discov
Zhao P, Zhang P.
europepmc   +1 more source